Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.25 (
MEKK1
)
1,856
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The Crohn's-disease-susceptibility protein,
NOD2
, coordinates signaling responses upon intracellular exposure to bacteria. Although
NOD2
is known to activate NFkappaB, little is known about the molecular mechanisms by which
NOD2
coordinates functionally separate signaling pathways such as NFkappaB, JNK, and p38 to regulate cytokine responses. Given that one of the characteristics of Crohn's disease is an altered cytokine response to normal bacterial flora, the coupling of signaling pathways could be important for Crohn's-disease pathophysiology. We find that a
MAP3K
, MEKK4, binds to RIP2 to sequester RIP2 from the
NOD2
signaling pathway. This MEKK4:RIP2 complex dissociates upon exposure to the
NOD2
agonist, MDP, allowing
NOD2
to bind to RIP2 and activate NFkappaB. MEKK4 thus sequesters RIP2 to inhibit the
NOD2
:RIP2 complex from activating NFkappaB signaling pathways, and Crohn's-disease-associated
NOD2
polymorphisms cannot compete with MEKK4 for RIP2 binding. Lastly, we find that MEKK4 helps dictate signal specificity downstream of
NOD2
activation as knockdown of MEKK4 in macrophages exposed to MDP causes increased NFkappaB activity, absent p38 activity, and hyporesponsiveness to TLR2 and TLR4 agonists. These biochemical findings suggest that basal inhibition of the
NOD2
-driven NFkappaB pathway by MEKK4 could be important in the pathogenesis of Crohn's disease.
...
PMID:MEKK4 sequesters RIP2 to dictate NOD2 signal specificity. 1877 59